NC
AXSM icon

NinePointTwo Capital’s Axsome Therapeutics AXSM Stock Holding History

NinePointTwo Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,599
Closed -$258K – 257
2023
Q2 		$258K Buy
+3,599
New +$265K 0.1% 112

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NinePointTwo Capital's AXSM Position: Q3 2023 in Review

NinePointTwo Capital sold out of Axsome Therapeutics (AXSM) in Q3 2023, closing a stake of 3,599 shares — an estimated $258K sold.

NinePointTwo Capital first reported a position in AXSM in Q2 2023 and held it in 1 quarter. The position peaked at $258K in Q2 2023. 226 funds tracked by Wall St. Rank hold AXSM as of Q3 2023.

  • NinePointTwo Capital reported no remaining Axsome Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 3,599 Axsome Therapeutics shares in Q3 2023, an estimated $258K.
  • NinePointTwo Capital first reported a position in Axsome Therapeutics in Q2 2023 and held it in 1 quarter.
  • NinePointTwo Capital's Axsome Therapeutics position peaked at $258K in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.